A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations
- Conditions
- HIV Infections
- Registration Number
- NCT00002430
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to compare two different anti-HIV drug combinations, one that contains nelfinavir (NFV) and one that does not. The best dosing schedule for indinavir (IDV) also will be studied.
- Detailed Description
Patients are stratified by screening plasma viral RNA results (50,000 copies/ml or below vs above 50,000 copies/ml) and randomized to 1 of 2 treatment arms. Group 1 receives IDV 3 times daily plus d4T/3TC twice daily. Group 2 receives IDV/NFV/d4T/3TC twice daily. Patients remain on study medications for 24 weeks and are seen at the clinic once every 4 weeks after entering the study. At each clinic visit, blood samples are taken to evaluate CD4 cell count and plasma HIV RNA levels.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 220
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (46)
Univ of Alabama School of Med
🇺🇸Montgomery, Alabama, United States
Ocean View Internal Medicine
🇺🇸Long Beach, California, United States
AIDS Healthcare Foundation
🇺🇸Los Angeles, California, United States
Tower ID Med Associates
🇺🇸Los Angeles, California, United States
Oasis Clinic / King Drew Med Ctr
🇺🇸Los Angeles, California, United States
Robert Scott MD
🇺🇸Oakland, California, United States
AIDS Community Research Consortium
🇺🇸Redwood City, California, United States
Saint Francis Mem Hosp / HIV Care Unit
🇺🇸San Francisco, California, United States
Pacific Horizons Med Group
🇺🇸San Francisco, California, United States
Kaiser Foundation Hospital
🇺🇸San Francisco, California, United States
Scroll for more (36 remaining)Univ of Alabama School of Med🇺🇸Montgomery, Alabama, United States